Medicare Plan For Lowering Insulin Costs Takes Aim At Benefit Design Instead Of List Prices
Executive Summary
The new payment demonstration in Part D reflects the increasing recognition that insurance benefit design has a major impact on insulin affordability.
You may also be interested in...
Civica Takes On The Challenge Of Insulin Affordability
The non-profit organization plans to make biosimilar versions of Lantus, Humalog and Novolog and sell them for no more than $30/vial.
US Medicare Insulin Demo Could Expand To Other Drugs
Eighty-eight insurers who offer Medicare Part D plans are interested in the demonstration project, which would limit insulin copays to $35.
US Medicare Insulin Demo Could Expand To Other Drugs
Eighty-eight insurers who offer Medicare Part D plans are interested in the demonstration project, which would limit insulin copays to $35.